Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kairos Pharma (KAPA) Non-Current Assets (2024 - 2025)

Kairos Pharma's Non-Current Assets history spans 2 years, with the latest figure at $1.2 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 27.89% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $1.2 million, down 27.89%, while the annual FY2025 figure was $1.2 million, 27.89% down from the prior year.
  • Non-Current Assets reached $1.2 million in Q4 2025 per KAPA's latest filing, down from $1.8 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $1.9 million in Q1 2025 to a low of $262000.0 in Q3 2024.